ReviewZhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology2026
[Advances in the diagnosis and treatment of patients with multidrug-resistant bacterial infections combined with severe liver disease].
Review in Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Effective antibiotic treatment is crucial for patients with severe liver disease combined with bacterial infections in the early stage. However, the incidence rate of multidrug-resistant bacteria (MDROs) infection in such patients is as high as 34%, and it is increasing year by year, becoming one of the main causes of antibiotic treatment failure and patient mortality. The main common MDROs in clinical practice are methicillin-resistant Staphylococcus aureus, carbapenem-resistant Enterobacteriaceae, vancomycin-resistant Enterococcus, and extended-spectrum β-lactamase-producing Enterobacteriaceae, with limited antimicrobial therapeutic options. Therefore, research on the diagnosis and treatment of MDRO infection can significantly improve the prognosis of patients with severe liver disease. The main risk factors for MDRO infections in these patients include frequent hospitalizations, invasive procedures, MDRO colonization, and repeated exposure to antimicrobial agents. The key measures to reduce MDRO infection are to strengthen nosocomial infection control, use antimicrobial agents rationally, conduct epidemiological surveillance, and actively screen colonized patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.